ipilimumab,interferon alfa-2b
biogen,bms
['e1609', 'melanoma']
join #aacr23 presentation "an integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma" based on #ncictep #clinicaltrial e1609, at 3:22 - 3:37pm edt this afternoon. more: 
Official Twitter account of NCI's Cancer Therapy Evaluation Program, providing updates to our trials research community. Part of @NIH. Privacy: https://t.co/9Aox3geiD8